Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Evelyn Rustia"'
Autor:
Maria Vutcovici Nicolae, Mei Dong, Teraneh Z. Jhaveri, Laura De Benedetti, Hanane Khoury, Lee Stern, Mellissa Williamson, Jason Beal, Matthew Radford, Mindy Chen, Siu-Chi Chang Sun, Evelyn Rustia, Mathias Schulz, Giri Ramsingh, Eduardo Sabate
Publikováno v:
HemaSphere, Vol 7, p e22327be (2023)
Externí odkaz:
https://doaj.org/article/e1220617744643478f1d954fcb3dccc9
Autor:
Evelyn Rustia, Amanda L. Wise, Sharon DeChenne, Ariel R. Topletz-Erickson, JoAl Mayor, Anthony Lee, Luke Walker, Ben Dailey, Layth I. Abdulrasool, Christopher J. Endres, Stephen C. Alley
Publikováno v:
Journal of Clinical Pharmacology
Tucatinib is a potent tyrosine kinase inhibitor selective for human epidermal growth factor receptor 2 (HER2) approved by the US Food and Drug Administration for the treatment of HER2‐positive metastatic breast cancer and in development for other H
Autor:
Evelyn Rustia, JoAl Mayor, Anthony J. Lee, Ariel R. Topletz-Erickson, Luke Walker, Hao Sun, Layth I. Abdulrasool, Christopher J. Endres
Publikováno v:
Cancer Research. 81:1371-1371
Background: Tucatinib (TUKYSA®) is a selective HER2-targeted tyrosine kinase inhibitor indicated in combination with trastuzumab and capecitabine for adult patients with metastatic HER2+ breast cancer who have received ≥1 prior HER2-based regimen,
Autor:
Sara M. Tolaney, Virginia F. Borges, Sara A. Hurvitz, Joyce O'Shaughnessy, Linda T. Vahdat, Noriyuki Masuda, D. Xie, Luke Walker, Evelyn Rustia, Antonio C. Wolff, Sherene Loi, Nadia Harbeck
Publikováno v:
Annals of Oncology. 32:S75
Autor:
Linda T. Vahdat, Sara M. Tolaney, Cassie Dong, Evelyn Rustia, Nadia Harbeck, Antonio C. Wolff, S.A. Hurvitz, Joyce O'Shaughnessy, Virginia F. Borges, Luke Walker, Norikazu Masuda, Sherene Loi
Publikováno v:
Cancer Research. 81:OT-28
Background - Tucatinib (TUC), an oral tyrosine kinase inhibitor (TKI) highly selective for HER2 with minimal inhibition of EGFR, is approved in the US for use in combination with trastuzumab (Tras) and capecitabine for treatment (tx) of adult patient
Autor:
Noriyuki Masuda, Antonio C. Wolff, Nadia Harbeck, Sherene Loi, Joyce O'Shaughnessy, S.A. Hurvitz, Virginia F. Borges, Luke Walker, Evelyn Rustia, Linda T. Vahdat, Sara M. Tolaney, Cassie Dong
Publikováno v:
Annals of Oncology. 31:S390
Autor:
Luke Walker, Layth I. Abdulrasool, Evelyn Rustia, Ariel R. Topletz-Erickson, JoAl Mayor, Christopher J. Endres, Anthony Lee
Publikováno v:
Cancer Research. 80:3015-3015
Background: Tucatinib (TUC) is a potent, highly selective investigational HER2 tyrosine kinase inhibitor in development for treatment of patients with HER2+ metastatic breast cancer (MBC). In HER2CLIMB (H2C), a pivotal study of patients with HER2+ MB
Autor:
Luke Walker, Virginia F. Borges, Linda T. Vahdat, Antonio C. Wolff, Evelyn Rustia, Cassie Dong, Nadia Harbeck, Sara M. Tolaney, Sherene Loi, Sara A. Hurvitz, Norikazu Masuda
Publikováno v:
Cancer Research. 80:OT2-01
Background: Tucatinib is an orally-available, reversible HER2 small molecule tyrosine kinase inhibitor (TKI) being developed as a novel treatment for patients with HER2+ metastatic breast cancer (mBC), including patients with brain metastases. Two ke
Autor:
Jean Sosna, Prakash Satwani, Esra Karamehmet, Diane George, Leah Violago, Andrew L. Kung, Evelyn Rustia, Zhezhen Jin, Chalitha Robinson, Monica Bhatia, Marc Foca, James Garvin
Publikováno v:
Pediatric Transplantation. 19:737-744
HHV-6 is an evolving pathogen in the field of AlloHCT. However, the impact of HHV-6 on AlloHCT outcomes remains to be elucidated. We studied the incidence and clinical impact of HHV-6 viremia in children following AlloHCT. One hundred consecutive chi
Autor:
Kara Gross Margolis, Sivan Kinberg, Alejandro Iglesias, Evelyn Rustia, Chana L. Glasser, Joseph A. Picoraro, Preti Jain, Kwame Anyane-Yeboa, Nancy S. Green
Publikováno v:
Journal of pediatric hematology/oncology. 38(7)
Severe congenital neutropenia type IV (SCN IV) is a syndrome of severe neutropenia, cardiac and urogenital defects, prominent superficial veins, facial dysmorphism, failure to thrive (FTT), and intermittent thrombocytopenia, caused by a glucose-6-pho